DMTK Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 5.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

DermTech Insider Trading History Chart

This chart shows the insider buying and selling history at DermTech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

DermTech Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 06/26/2024 09:59 PM ET

This chart shows the closing price history over time for DMTK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for DermTech (NASDAQ:DMTK)

20.45% of DermTech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DMTK by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total InflowsTotal Outflows
DermTech logo
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
Read More on DermTech

Today's Range

Now: N/A

50 Day Range

MA: $0.19
Low: $0.05
High: $0.42

52 Week Range

Now: N/A

Volume

3,662,300 shs

Average Volume

1,065,175 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48

Who are the company insiders with the largest holdings of DermTech?

DermTech's top insider shareholders include:
  1. Kevin M Sun (CFO)
  2. Todd Michael Wood (Insider)
  3. Claudia Ibarra (COO)
  4. Ramin Akhavan (General Counsel)
Learn More about top insider investors at DermTech.